These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 37865804

  • 1. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
    Liang M, Sun Z, Chen X, Wang L, Wang H, Qin L, Zhao W, Geng B.
    J Exp Clin Cancer Res; 2023 Oct 21; 42(1):275. PubMed ID: 37865804
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS.
    Gut; 2018 May 21; 67(5):931-944. PubMed ID: 28939663
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
    Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, Liu B, Dubinett SM.
    Cancer Res; 2021 Jun 15; 81(12):3295-3308. PubMed ID: 33853830
    [Abstract] [Full Text] [Related]

  • 8. TRIM28 promotes tumor growth and metastasis in breast cancer by targeting the BRD7 protein for ubiquitination and degradation.
    Xue C, Meng H, Niu W, Li M, Wei J, Chen S, Zheng L, Duan Y, Deng H, Tang F, Fan S, Tan M, Xiong W, Zhou M.
    Cell Oncol (Dordr); 2024 Oct 15; 47(5):1973-1993. PubMed ID: 39222175
    [Abstract] [Full Text] [Related]

  • 9. The Tian-Men-Dong decoction suppresses the tumour-infiltrating G-MDSCs via IL-1β-mediated signalling in lung cancer.
    Su L, Zhang F, Liu MX, Li H, Li Q, Zhu YZ, Hou YF, Chen X, Wang XY, Qian CM, Yao C, Wang LX, Jiao XN, Zhu XD, Xu ZH, Zou CP.
    J Ethnopharmacol; 2023 Sep 15; 313():116491. PubMed ID: 37072091
    [Abstract] [Full Text] [Related]

  • 10. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT.
    JCI Insight; 2019 Apr 04; 4(7):. PubMed ID: 30944253
    [Abstract] [Full Text] [Related]

  • 11. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
    Liu X, Tang R, Xu J, Tan Z, Liang C, Meng Q, Lei Y, Hua J, Zhang Y, Liu J, Zhang B, Wang W, Yu X, Shi S.
    Gut; 2023 Nov 24; 72(12):2329-2343. PubMed ID: 37541772
    [Abstract] [Full Text] [Related]

  • 12. Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways.
    Kong Q, Ma M, Zhang L, Liu S, He S, Wu J, Liu B, Dong J.
    Phytomedicine; 2023 Feb 24; 110():154638. PubMed ID: 36621167
    [Abstract] [Full Text] [Related]

  • 13. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
    Zhao Z, Qin J, Qian Y, Huang C, Liu X, Wang N, Li L, Chao Y, Tan B, Zhang N, Qian M, Li D, Liu M, Du B.
    J Hematol Oncol; 2024 Feb 24; 17(1):9. PubMed ID: 38402237
    [Abstract] [Full Text] [Related]

  • 14. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
    Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S, Deshane JS.
    Oncotarget; 2016 Nov 15; 7(46):75407-75424. PubMed ID: 27705910
    [Abstract] [Full Text] [Related]

  • 15. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
    Kong Q, Zhu H, Gong W, Deng X, Liu B, Dong J.
    J Ethnopharmacol; 2024 Jan 30; 319(Pt 1):117183. PubMed ID: 37739106
    [Abstract] [Full Text] [Related]

  • 16. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS.
    J Thorac Oncol; 2019 Jun 30; 14(6):1046-1060. PubMed ID: 30771521
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
    Liang Y, Wang W, Zhu X, Yu M, Zhou C.
    Sci Rep; 2022 Jun 10; 12(1):9619. PubMed ID: 35688951
    [Abstract] [Full Text] [Related]

  • 18. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
    Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL.
    Front Immunol; 2023 Jun 10; 14():1161869. PubMed ID: 37449205
    [Abstract] [Full Text] [Related]

  • 19. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
    Zhang M, Yang W, Wang P, Deng Y, Dong YT, Liu FF, Huang R, Zhang P, Duan YQ, Liu XD, Lin D, Chu Q, Zhong B.
    Nat Commun; 2020 Nov 30; 11(1):6119. PubMed ID: 33257678
    [Abstract] [Full Text] [Related]

  • 20. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T, Liu S, Hanna NH, Jalal S, Ding X, Wan J, Yan C, Du H.
    J Immunother Cancer; 2023 Mar 30; 11(3):. PubMed ID: 36914206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.